Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,973 shares of the medical research company’s stock after acquiring an additional 237 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Amgen were worth $3,536,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Hoxton Planning & Management LLC lifted its holdings in Amgen by 5.7% in the first quarter. Hoxton Planning & Management LLC now owns 739 shares of the medical research company’s stock valued at $210,000 after acquiring an additional 40 shares during the last quarter. First Financial Corp IN lifted its stake in shares of Amgen by 15.7% in the 1st quarter. First Financial Corp IN now owns 390 shares of the medical research company’s stock valued at $111,000 after purchasing an additional 53 shares during the last quarter. Sound Income Strategies LLC grew its holdings in shares of Amgen by 17.4% during the 1st quarter. Sound Income Strategies LLC now owns 1,080 shares of the medical research company’s stock worth $307,000 after purchasing an additional 160 shares during the period. Elevated Capital Advisors LLC increased its position in shares of Amgen by 8.0% during the 1st quarter. Elevated Capital Advisors LLC now owns 1,328 shares of the medical research company’s stock worth $378,000 after purchasing an additional 98 shares during the last quarter. Finally, Sovereign Financial Group Inc. raised its holdings in Amgen by 11.0% in the 1st quarter. Sovereign Financial Group Inc. now owns 1,451 shares of the medical research company’s stock valued at $413,000 after buying an additional 144 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.9 %

Shares of NASDAQ AMGN opened at $319.66 on Wednesday. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85. The company has a market capitalization of $171.48 billion, a price-to-earnings ratio of 45.67, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The business has a 50-day moving average of $325.93 and a two-hundred day moving average of $313.11.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The business had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. Amgen’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.00 EPS. On average, analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.82%. Amgen’s dividend payout ratio is currently 128.57%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and lifted their price target for the company from $320.00 to $333.00 in a research report on Monday, October 14th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. TD Cowen upped their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $332.55.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.